Systemic treatment of hepatocellular carcinoma: An EASL position paper
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Authors
Keywords
liver cancer, immunotherapy, tyrosine kinase inhibitors, immune-checkpoint inhibitors, hepatoma, liver toxicity
Journal
JOURNAL OF HEPATOLOGY
Volume 75, Issue 4, Pages 960-974
Publisher
Elsevier BV
Online
2021-07-11
DOI
10.1016/j.jhep.2021.07.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- End-points in clinical trials for liver cancer and their value in evidence based clinical decision making: an unresolved Gordian knot.
- (2021) Jordi Bruix JOURNAL OF HEPATOLOGY
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
- (2021) Zhenggang Ren et al. LANCET ONCOLOGY
- When Can Intermediate Outcomes Be Used as Surrogate Outcomes?
- (2020) David L. DeMets et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
- (2020) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
- (2020) Robin K. Kelley et al. ADVANCES IN THERAPY
- The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT
- (2020) Manuel de la Torre-Aláez et al. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
- Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.
- (2020) Arndt Vogel et al. JOURNAL OF CLINICAL ONCOLOGY
- International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis
- (2020) Álvaro Díaz‐González et al. LIVER INTERNATIONAL
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review
- (2020) E. Klajer et al. SEMINARS IN ONCOLOGY
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- (2020) Charles Dolladille et al. JAMA Oncology
- Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma
- (2020) Robin Kate Kelley et al. CLINICAL CANCER RESEARCH
- A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
- (2020) Katy Cooper et al. BRITISH JOURNAL OF CANCER
- Treatment-related toxicity predicts for improved outcome in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitor therapy
- (2020) David J. Pinato et al. JOURNAL OF HEPATOLOGY
- Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
- (2020) Chang Gon Kim et al. JOURNAL OF HEPATOLOGY
- Treatment after progression in the era of immunotherapy
- (2020) Salem Billan et al. LANCET ONCOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
- (2020) Robin Kate Kelley et al. ESMO Open
- Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice
- (2020) Jordi Rimola et al. EUROPEAN JOURNAL OF RADIOLOGY
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre
- (2019) Friedrich Foerster et al. United European Gastroenterology Journal
- Association between overall survival and adverse events with lenvatinib treatment in patients with hepatocellular carcinoma (REFLECT).
- (2019) Max W. Sung et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma
- (2019) Lorenza Rimassa et al. CANCER TREATMENT REVIEWS
- Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.
- (2019) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
- (2019) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
- (2019) Bishal Gyawali et al. JAMA Internal Medicine
- Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
- (2019) Massimo Iavarone et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
- (2019) Swetha Kambhampati et al. CANCER
- Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
- (2019) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Insights into the success and failure of systemic therapy for hepatocellular carcinoma
- (2019) Jordi Bruix et al. Nature Reviews Gastroenterology & Hepatology
- Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
- (2019) Masatoshi Kudo et al. Cancers
- Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease
- (2019) Melissa Palmer et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- 755PAlpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial
- (2019) J Bruix et al. ANNALS OF ONCOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
- (2019) Angel Alsina et al. Liver Cancer
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Clinical states of cirrhosis and competing risks
- (2018) Gennaro D'Amico et al. JOURNAL OF HEPATOLOGY
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of checkpoint inhibitors in liver transplant recipients
- (2018) Stefan Munker et al. United European Gastroenterology Journal
- A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology
- (2018) Alyson Haslam et al. EUROPEAN JOURNAL OF CANCER
- Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials
- (2018) Run-Cong Nie et al. EUROPEAN JOURNAL OF CANCER
- Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study
- (2018) David J. Pinato et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
- (2017) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- RECIST — learning from the past to build the future
- (2016) Saskia Litière et al. Nature Reviews Clinical Oncology
- Expanding consensus in portal hypertension
- (2015) Roberto de Franchis JOURNAL OF HEPATOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST
- (2014) Maria Reig et al. SEMINARS IN LIVER DISEASE
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients
- (2012) Massimiliano Berretta et al. ANTI-CANCER DRUGS
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression
- (2012) G. R. Oxnard et al. JNCI-Journal of the National Cancer Institute
- Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
- (2010) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers and surrogate end points—the challenge of statistical validation
- (2010) Marc Buyse et al. Nature Reviews Clinical Oncology
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma
- (2009) Alejandro Forner et al. CANCER
- Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis
- (2009) Marcus Alexander Wörns et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
- (2009) Antonius A. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
- (2009) Youjin Je et al. LANCET ONCOLOGY
- Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
- (2009) M. Pinter et al. ONCOLOGIST
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search